Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta …
Background Long‐acting bronchodilators such as long‐acting β‐agonist (LABA), long‐
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …
Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
MIA Aziz, LE Tan, DBC Wu, F Pearce… - … journal of chronic …, 2018 - Taylor & Francis
Purpose To assess the comparative efficacy of short-acting muscarinic antagonists (SAMAs),
long-acting muscarinic antagonists (LAMAs), LAMA in combination with long-acting beta …
long-acting muscarinic antagonists (LAMAs), LAMA in combination with long-acting beta …
Efficacy and safety of budesonide/glycopyrronium/formoterol fumarate versus other triple combinations in COPD: a systematic literature review and network meta …
A Bourdin, N Molinari, GT Ferguson, B Singh… - Advances in …, 2021 - Springer
In patients with chronic obstructive pulmonary disease (COPD) who experience further
exacerbations or symptoms, despite being prescribed dual long-acting muscarinic …
exacerbations or symptoms, despite being prescribed dual long-acting muscarinic …
Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis
M Schlueter, N Gonzalez-Rojas… - Therapeutic …, 2016 - journals.sagepub.com
Background: A number of long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist
(LABA) fixed-dose combinations (FDCs) for treatment of moderate-to-very severe chronic …
(LABA) fixed-dose combinations (FDCs) for treatment of moderate-to-very severe chronic …
A Network Meta-Analysis of Long-Acting Muscarinic Antagonist (LAMA) and Long-Acting β2-Agonist (LABA) Combinations in COPD
KYJ Sion, EL Huisman, YS Punekar, I Naya… - Pulmonary …, 2017 - Springer
Introduction Comparative data on the efficacies of long-acting muscarinic antagonist (LAMA)
and long-acting β 2-agonist (LABA) combinations for the treatment of moderate-to-very …
and long-acting β 2-agonist (LABA) combinations for the treatment of moderate-to-very …
Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review
JL Lopez-Campos, C Calero-Acuña… - … Journal of Chronic …, 2017 - Taylor & Francis
Objective The combination of a long-acting muscarinic antagonist (LAMA) and a long-acting
β2-agonist (LABA) in a single inhaler is a viable treatment option for patients with chronic …
β2-agonist (LABA) in a single inhaler is a viable treatment option for patients with chronic …
Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long …
MK Siddiqui, P Shukla, M Jenkins… - Therapeutic …, 2019 - journals.sagepub.com
Background: Dual bronchodilation with a long-acting muscarinic antagonist (LAMA)/long-
acting β2-agonist (LABA) fixed-dose combination (FDC) is an established treatment strategy …
acting β2-agonist (LABA) fixed-dose combination (FDC) is an established treatment strategy …
Efficacy and safety of LAMA/LABA fixed-dose combination therapies in chronic obstructive pulmonary disease: a systematic review of direct and indirect treatment …
JR Hurst, K Gruffydd-Jones, M Biswas… - … Journal of Chronic …, 2020 - Taylor & Francis
Background This literature review assessed comparative efficacy and safety of long-acting
muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) fixed-dose combinations (FDCs) …
muscarinic antagonist/long-acting β2-agonist (LAMA/LABA) fixed-dose combinations (FDCs) …
Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD
MLK Han, R Ray, J Foo, C Morel, B Hahn - NPJ Primary Care …, 2018 - nature.com
Dual bronchodilator maintenance therapy may benefit patients with moderate-to-severe
chronic obstructive pulmonary disease (COPD) versus long-acting muscarinic antagonist …
chronic obstructive pulmonary disease (COPD) versus long-acting muscarinic antagonist …
Cost-effectiveness of fixed-dose combinations therapies for chronic obstructive pulmonary disease treatment
M Capel, M Mareque, CJ Álvarez, L Lindner… - Clinical Drug …, 2018 - Springer
Abstract Background and Objective Chronic obstructive pulmonary disease (COPD), a
progressive lung disorder associated with decline of respiratory function, affects 10.2% of …
progressive lung disorder associated with decline of respiratory function, affects 10.2% of …